<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bariatric Product Guide &#187; CHMP</title>
	<atom:link href="http://www.bariatricproductguide.com/blog/tag/chmp/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bariatricproductguide.com/blog</link>
	<description>A comprehensive guide to bariatric products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 08:51:06 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>GSK receives positive opinion for alli from CHMP</title>
		<link>http://www.bariatricproductguide.com/blog/2008/10/30/gsk-receives-positive-opinion-for-alli-from-chmp/</link>
		<comments>http://www.bariatricproductguide.com/blog/2008/10/30/gsk-receives-positive-opinion-for-alli-from-chmp/#comments</comments>
		<pubDate>Thu, 30 Oct 2008 07:31:24 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Anti-Obesity Drugs]]></category>
		<category><![CDATA[alli 60mg]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[orlistat]]></category>
		<category><![CDATA[weight loss]]></category>

		<guid isPermaLink="false">http://www.bariatricproductguide.com/blog/2008/10/30/gsk-receives-positive-opinion-for-alli-from-chmp/</guid>
		<description><![CDATA[The Committee for Medicinal Products for Human Use (CHMP) has given positive opinion as a non-prescription product to GlaxoSmithKline’s alli (orlistat 60 mg). This takes the product to the stage of proposal for final approval by the European Commission. A marketing authorization will follow that. On the grant of license, alli 60 mg would become [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.bariatricproductguide.com/blog/wp-content/uploads/2008/10/gsk.png" align="left" height="77" hspace="5" vspace="5" width="200" />The Committee for Medicinal Products for Human Use (CHMP) has given positive opinion as a non-prescription product to<a href="http://www.gsk.com"> GlaxoSmithKline</a>’s alli (orlistat 60 mg). This takes the product to the stage of proposal for final approval by the European Commission. A marketing authorization will follow that. On the grant of license, alli 60 mg would become the first aid for weight loss to be available without prescription across Europe. It will be indicated for people above the age of 18 with a BMI more than 28 kg/m2.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.bariatricproductguide.com/blog/2008/10/30/gsk-receives-positive-opinion-for-alli-from-chmp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
